Takeda News

Takeda announced that its dengue vaccine, QDENGA, may be available in the market by the first half of 2027, as local processes are being completed. A partnershi

The U.S. Food and Drug Administration (FDA) has approved Orzeyful (oveporexton), the first drug to treat a cause of narcolepsy by targeting the orexin pathway.

India's drug regulator has approved Takeda's Qdenga, making it the first dengue vaccine available in the country, with expected availability in the first half o

India has approved Takeda's two-dose QDENGA vaccine for dengue, which can be administered to individuals aged 4 to 60 years without prior screening and protects

India's first dengue vaccine, Qdenga by Takeda, has been approved by the DCGI for individuals aged 4 to 60.